We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Varian Medical's ProBeam Platform Gains Traction in Russia
Read MoreHide Full Article
Varian Medical Systems, Inc. recently announced that St. Petersburg Center of Nuclear Medicine of the Sergey Berezin Medical Institute concluded its first pediatric patient treatment with the company’s flagship ProBeam proton therapy system. Notably, the center is expected to treat approximately 1,000 patients each year.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick at the moment.
What is ProBeam Proton Therapy System?
Varian Medical's ProBeam system is a leading platform in advanced cancer-care technologies. This is the world's first commercially available pencil beam scanning system, which is the most precise form of proton therapy available.
The platform comes under the company’s particle therapy business. It delivers intensity-modulated proton therapy (IMPT), which is considered to be better than the other legacy proton therapy delivery methods.
In the last quarter Varian Medical booked two new proton orders, one at the University of Alabama at Birmingham and one at the Sylvester Comprehensive Cancer Center at the University of Miami. Management confirmed that both orders were for the ProBeam systems.
Over the past year, Varian Medical outperformed its industry in terms of price performance.
The company returned 48.9%, comparing favorably with the sub-industry’s gain of 26.8%. Also, the current return is higher than the S&P 500’s growth of 23.5%.
Varian Medical’s solid performance in the Oncology business— ProBeam proton therapy, improving margins and the launch of Halcyon radiotherapy treatment system are the key highlights at the moment.
Strong revenue opportunity from its various Oncology and Imaging Component products, growing adoption of Proton Therapy, strong overseas presence, particularly in emerging countries and new partnership deals are also positives.
Other Key Picks
Other top-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and PerkinElmer .
athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Varian Medical's ProBeam Platform Gains Traction in Russia
Varian Medical Systems, Inc. recently announced that St. Petersburg Center of Nuclear Medicine of the Sergey Berezin Medical Institute concluded its first pediatric patient treatment with the company’s flagship ProBeam proton therapy system. Notably, the center is expected to treat approximately 1,000 patients each year.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick at the moment.
What is ProBeam Proton Therapy System?
Varian Medical's ProBeam system is a leading platform in advanced cancer-care technologies. This is the world's first commercially available pencil beam scanning system, which is the most precise form of proton therapy available.
The platform comes under the company’s particle therapy business. It delivers intensity-modulated proton therapy (IMPT), which is considered to be better than the other legacy proton therapy delivery methods.
In the last quarter Varian Medical booked two new proton orders, one at the University of Alabama at Birmingham and one at the Sylvester Comprehensive Cancer Center at the University of Miami. Management confirmed that both orders were for the ProBeam systems.
Varian Medical Systems, Inc. Price
Varian Medical Systems, Inc. Price | Varian Medical Systems, Inc. Quote
Favorable Stock Performance
Over the past year, Varian Medical outperformed its industry in terms of price performance.
The company returned 48.9%, comparing favorably with the sub-industry’s gain of 26.8%. Also, the current return is higher than the S&P 500’s growth of 23.5%.
Varian Medical’s solid performance in the Oncology business— ProBeam proton therapy, improving margins and the launch of Halcyon radiotherapy treatment system are the key highlights at the moment.
Strong revenue opportunity from its various Oncology and Imaging Component products, growing adoption of Proton Therapy, strong overseas presence, particularly in emerging countries and new partnership deals are also positives.
Other Key Picks
Other top-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and PerkinElmer .
Bio-Rad Laboratories sports a Zacks Rank of #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.
athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>